The http://www.vhebron.net/oncohematologia-pediatrica" Paediatric Oncology and Haematology Service of Maternal and Child Hospital of Vall d'Hebron will soon start the project, which must be completed to reform, adapt and extend the area of paediatric transplantation of haematopoietic stem cells thanks to the donation made by http://www.noel.es/ca/" Noel Alimentaria, through its foundation, Albert Bosch Foundation. The company, specialized in meat products, has gathered 200,000 euros, one of the objectives proposed in the framework of its 75th anniversary. In 2015 Noel Alimentaria and the Albert Bosch Foundation launched an ambitious new collaborative project with the Vall d'Hebron Hospital to reform and expand the area of stem cell transplantation. The challenge was to get the 200,000 euros needed to achieve this. The collaboration of 131 companies and individuals have made it possible to successfully close this campaign fundraising. The work will take into account all clinical and technological improvements that allow excellent assistance to patients, getting to improve the quality of care they receive and their quality of life and that of their families during treatment. The manager of the University Hospital Vall d'Hebron, Dr. Vicenç Martínez Ibáñez, highlighted the importance of the collaboration with entities such as the Albert Bosch Foundation. "Joint projects and developed with Albert Bosch Foundation are a good example of how civil society and the Hospital can work together to provide the best care to patients and a frontline research to develop new treatments". In addition, the Head of Paediatric Oncology and Haematology, Dr. Josep Sánchez de Toledo, explained that "for many years, the Albert Bosch Foundation is an indispensable ally in the development of areas of research in childhood cancer done in the Vall d'Hebron Research Institute (VHIR) and, specially in the field of soft tissue sarcomas in children". At the same time "all their projects, both clinical and research, aim to ensure quality of care and of life for children and their families".Anna Bosch, president of the Albert Bosch Foundation, wanted to thank all the participating partner companies and has been very optimistic about the future. "The contribution of each of the companies and individuals who have contributed to this donation is key to make more comfortable the long stays that patients spend in this unit. In the foundation we are convinced that together we will continue adding to make it easier and pleasant their recovery".Haematopoietic stem cell transplantationThe haematopoietic stem cell transplantation is a procedure that is used to fight malignancies such as leukaemia and myelodysplastic syndromes and other non-malignant as congenital and acquired marrow aplasia, congenital immunodeficiencies, some haemoglobinopathies, such as thalassemia and sickle cell disease, or some metabolic storage diseases. The treatment involves the suppression of the medulla of the patient, producing defective cells by administering high doses of chemotherapy. After completing this step, it is replaced with a healthy medulla donated by a donor (allogeneic transplant) or the same patient (autologous transplant).This procedure removes the body's natural defences and forces to keep the patient in solitary confinement, transplant rooms, where they can spend a period of time that, on average, lengthens between 3 weeks and 2 months.The Paediatric Oncology and Haematology Service of Maternal and Child Hospital is a leader in the treatment of cancer in childhood and adolescence. It is the service that treats most cases in the country, according to the Spanish Registry of Childhood Tumours (RETI). In 1984 the first transplant of haematopoietic stem cells was performed. Today, it is the state referral centre for this procedure, and has established itself as the one who has performed the most, more than 1,200, an average of 40 per year.Albert Bosch Foundation promotes research and development of medical solutions against childhood cancer. The foundation, which was founded in 2004 linked to Noel Alimentaria, mainly supports research with stem cells in highly resistant childhood tumors such as rhabdomyosarcoma and neuroblastoma among others. The company mainly supports translational research in the field of soft tissue sarcomas and, especially, in those high-risk tumours or refractory to treatment. Research in the field of molecular biology, is working to improve diagnosis, identify prognostic factors and design new drugs to new therapeutic targets, what we know as precision medicine, in order to increase cure rates and lower side effects.The joint work of the foundation with Vall d'Hebron has also helped to develop the deployment of foetal surgery in the centre. In this field, projects related to reproductive organs and congenital and acquired spinal cord injuries and foetal surgery itself are promoted.For more than 12 years ago, Noel Alimentaria and Albert Bosch Foundation have worked with the aim of improving the quality of life of children and their families through research done at the Research Institute of the University Hospital Vall d'Hebron.